CO-MOUNT-ELBERT-CAPITAL
26.3.2019 12:02:11 CET | Business Wire | Press release
Mount Elbert Capital Partners (“Mount Elbert”), a real-assets private equity firm with specialized capabilities in internet infrastructure, today announced that it has completed the final closing of its first fund, Mount Elbert Capital Partners Fund 1 (”Fund 1”). The Fund closed on equity commitments totaling $382 million, surpassing the initial target of $290 million. In raising Fund 1, Mount Elbert attracted a range of global investors, including pension funds, endowments, and family offices.
Fund 1 was 22% invested at December 31, 2018, investing alongside global institutional investors GIC and OPTrust in EdgeCore Internet Real Estate (“EdgeCore”). EdgeCore is an investment vehicle developing, acquiring, and operating data centers and related infrastructure, and has been initially capitalized with over $900 million of equity targeted to support approximately $2.0 billion in data center development. In addition to Mount Elbert’s investment through Fund 1, Mount Elbert affiliates serve as General Partner of and provide asset-management, development, and leasing services to EdgeCore.
“We appreciate the support of our investors and the trust they place in us. We are pleased to have been oversubscribed in Fund 1, and we believe the investment environment for the Fund is attractive,” said Tom Ray, Chairman, and CEO of Mount Elbert. “We are also pleased to have established the operating capabilities inherent in Mount Elbert’s service affiliates; we view these capabilities as invaluable and have positioned them to scale and support further investment. Experienced as both investors and operators, we work to leverage our industry relationships, investment vision, and operational insight and resources to discern a deeper layer of opportunities and risks in an investing environment featuring an abundance of both. We remain focused upon generating attractive risk-adjusted returns by sourcing attractive investment opportunities and catalyzing elevated execution through our highly driven operational capability and ethos.”
Jefferies LLC served as exclusive global placement agent and financial advisor for Mount Elbert.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities.
About Mount Elbert
Mount Elbert Capital Partners is a real-assets private equity firm with specialized capabilities in internet infrastructure, including data centers, colocation and interconnection assets and operating companies, and related assets. Our founders and investment professionals have experience evaluating, making and managing investments in real assets with an aggregate value exceeding $20 billion across the US, Europe, and Asia, with more than $15.0 billion in internet infrastructure. For more information, visit www.mountelbert.com .
About EdgeCore Internet Real Estate
EdgeCore Internet Real Estate is a preeminent U.S. developer, owner and operator of highly scalable, cloud-connected, wholesale data center campuses, providing solutions to the Global 2000, including hyperscale cloud and internet companies. EdgeCore is currently developing data center campuses in Dallas, Phoenix, Northern Virginia, Reno, and Silicon Valley with plans to develop campuses in additional markets. Each of the Company’s five initial campuses is designed to support between 80 and 225 MW of critical load, representing total capacity exceeding 800 MW across the Company’s current platform. EdgeCore is committed to enabling the growth and supporting the rigorous performance requirements of its customers leveraging ready-for-service capacity and bespoke build-to-suit solutions across the U.S. For more information, visit www.edgecore.com or follow us on Twitter or LinkedIn .
About GIC
GIC is a leading global investment firm with well over US$100 billion in assets under management. Established in 1981 to secure the financial future of Singapore, the firm manages Singapore’s foreign reserves. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including real estate, private equity, equities and fixed income. GIC has investments in over 40 countries and has been investing in emerging markets for more than two decades. Headquartered in Singapore, GIC employs close to 1,500 people across 10 offices in key financial cities worldwide. For more information about GIC, please visit www.gic.com.sg .
About OPTrust
A fully funded plan with net assets of over $20 billion, OPTrust invests and manages one of Canada’s largest pension funds and administers the OPSEU Pension Plan, a defined benefit plan with over 92,000 members and retirees.
OPTrust is a global investor in a broad range of asset classes including Canadian and foreign equities, fixed income, real estate, infrastructure and private markets, and has a team of highly experienced investment professionals located in Toronto, London and Sydney. As a pension management organization, OPTrust’s mission is to pay pensions today, preserve pensions for tomorrow. For more information, please visit www.optrust.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190326005303/en/
Contact:
Mount Elbert Capital Partners Claire Rowberry claire@clearcommsc.com +1 617 785 5571
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom